摘要
口服核苷（酸）类似物和注射干扰素抗病毒已成为慢性乙型肝炎（乙肝）近年来治疗的主要方法。在核苷（酸）类似物中,拉米夫定应用时间最长,耐药者最多。本文就口服核苷（酸）类似物治疗拉米夫定耐药慢性乙型肝炎的研究报道做一综述,为临床合理用药提供依据。
Abstract： As the first oral nucleoside analogue which was approved for the treatment of chronic hepatitis B （CHB）, lamivudine is widely used for its high efficacy, fewer side effects and low cost. However, the in- creasing incidence of lamivudine-resistant CHB patients brings new challenges. Many scholars have turned to the monotherapy or combined therapy by using other nucleos/tide analogues. Meta-analysis of published papers in recent years indicated that lamivudine resistant CHB patients often have higher rates of resistance to ente- eavir or adefovir dipivoxil, and switching to tenofovir needs further clinical verification. Combination therapy of nucleos/tide analogues is the widely used approach. Combination therapy of telbivudine and adefovir seems superior to other combinations. Adefovir dipivoxil plays a key role in each combination therapy.
出处
《中国病毒病杂志》
CAS
2013年第4期317-320,共4页
Chinese Journal of Viral Diseases
关键词
核苷(酸)类似物
拉米夫定耐药
慢性乙型肝炎
Nucleos/tide analogues Lamivudine resistance
Chronic hepatitis B
Combination therapy
